par Agostinetto, Elisa 
;Losurdo, Agnese;Marta, Guilherme Nader;Santoro, Armando;Punie, Kevin;Barroso, Romualdo;Popovic, Lazar;Solinas, Cinzia ;Kok, Marleen;de Azambuja, Evandro ;Lambertini, Matteo
Référence Expert opinion on investigational drugs, 31, 6, page (567-591)
Publication Publié, 2022-12-01
;Losurdo, Agnese;Marta, Guilherme Nader;Santoro, Armando;Punie, Kevin;Barroso, Romualdo;Popovic, Lazar;Solinas, Cinzia ;Kok, Marleen;de Azambuja, Evandro ;Lambertini, Matteo Référence Expert opinion on investigational drugs, 31, 6, page (567-591)
Publication Publié, 2022-12-01
Article révisé par les pairs
| Titre: |
|
| Auteur: | Agostinetto, Elisa; Losurdo, Agnese; Marta, Guilherme Nader; Santoro, Armando; Punie, Kevin; Barroso, Romualdo; Popovic, Lazar; Solinas, Cinzia; Kok, Marleen; de Azambuja, Evandro; Lambertini, Matteo |
| Informations sur la publication: | Expert opinion on investigational drugs, 31, 6, page (567-591) |
| Statut de publication: | Publié, 2022-12-01 |
| Sujet CREF: | Pharmacologie |
| Mots-clés: | Atezolizumab |
| durvalumab | |
| immune-checkpoint inhibitors | |
| immunotherapy | |
| nivolumab | |
| pembrolizumab | |
| triple negative breast cancer | |
| Note générale: | SCOPUS: re.j |
| Langue: | Anglais |
| Identificateurs: | urn:issn:1354-3784 |
| info:doi/10.1080/13543784.2022.2049232 | |
| info:scp/85126369292 | |
| info:pmid/35240902 |
